-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – JANX-008 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - JANX-008 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. JANX-008 in Non-Small Cell Lung Cancer Drug Details: JANX-008...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BGB-16673 in Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BGB-16673 in Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BGB-16673 in Chronic Lymphocytic Leukemia (CLL) Drug Details: BGB-16673...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BGB-16673 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BGB-16673 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BGB-16673 in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Drug Details: BGB-16673...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RLY-2608 in Cervical Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RLY-2608 in Cervical Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RLY-2608 in Cervical Cancer Drug Details: RLY-2608 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ivonescimab in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ivonescimab in Non-Small Cell Lung Cancer Drug Details: Ivonescimab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dapansutrile in Osteoarthritis Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dapansutrile in Osteoarthritis Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dapansutrile in Osteoarthritis Pain Drug Details: Dapansutrile (OLT-1177) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dapansutrile in Systolic Heart Failure
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dapansutrile in Systolic Heart Failure report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dapansutrile in Systolic Heart Failure Drug Details: Dapansutrile (OLT-1177) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Abobotulinumtoxina in Migraine
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Abobotulinumtoxina in Migraine report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Abobotulinumtoxina in Migraine Drug Details: Abobotulinumtoxin A (Dysport, Botulinum Toxin Type A, Azzalure)...
-
Company Insights
Innovation and Patenting activity of CEL-SCI Corp Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of CEL-SCI Corp Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...